– After Median Follow-Up of 11.5 Months, 73 Percent of Patients Had Confirmed Tumor Response with Majority of Responses Still Ongoing; No New Safety Signals Observed for the Combination – – Findings To Be Presented During an Oral Session at the 2020...
VANCOUVER, British Columbia, Feb. 12, 2020 (GLOBE NEWSWIRE) — WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to announce its plan to initiate a Phase I clinical trial for Berubicin in...
TOKYO and NEW YORK, Feb. 11, 2020 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) announced today results of the final overall survival (OS) analysis from the Phase 3...
Investigation underway into unexpected and inconsistent findings that may have negatively impacted results reported in TRILOGY 1 Announces plans to seek FDA guidance prior to unblinding TRILOGY 2 data, which is expected to delay reporting of TRILOGY 2 topline results...
Oxurion NV (OXUR), a biopharmaceutical company developing next generation therapies designed to treat patients with diabetic eye disease, today announces that further positive topline data from a Phase 1 study with THR-687, a novel, potent, pan-RGD integrin antagonist...
Email
Text